Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential

Journal of Medicinal Chemistry

Volumn 41, Issue 17, 1998, Pages 3103-3127

  Nargund, Ravi P ^a,f,g   Patchett, Arthur A ^a,d   Bach, Mark A ^a,b,c,d   Murphy, M Gail ^a,e   Smith, Roy G ^a,c,h,i  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f INDIANA UNIVERSITY   (United States)

^g Indiana University ^*

^h UNIVERSITY OF LONDON   (United Kingdom)

ⁱ VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; IBUTAMOREN; L 163255; SPIROINDOLINE SULFONAMIDE; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG DESIGN; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE SUBSTITUTION; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; GROWTH HORMONE-RELEASING HORMONE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEIN CONFORMATION; RECEPTORS, SOMATOTROPIN;

EID: 0032514481     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970342o     Document Type: Review

References (233)

1. For a comprehensive review on the actions of GH and its regulation see: (a) Rosen, T.; Johannsson, G.; Johansson, J.-O.; Bengtsson, B.-A. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. Horm. Res. 1995, 43, 93-99. (b) Strobl, J. S.; Thomas, M. J. Human growth hormone. Pharmacol. Rev. 1993, 46, 1-34.
2. For a comprehensive review on the actions of GH and its regulation see: (a) Rosen, T.; Johannsson, G.; Johansson, J.-O.; Bengtsson, B.-A. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. Horm. Res. 1995, 43, 93-99. (b) Strobl, J. S.; Thomas, M. J. Human growth hormone. Pharmacol. Rev. 1993, 46, 1-34.
3. Rudling, M.; Norstedt, G.; Olivecrona, H.; Reihner, E.; Gustafsson, J. A.; Angelin, B. Importance of growth hormone for the induction of hepatic low-density lipoprotein receptors. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6983-6987.
4. Rosen, T.; Bengtsson, B.-A. Premature death due to mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336, 285-288.
5. Gelato, M. C. Growth hormone-insulin like growth factor I and immune function. Trends Endocrinol. Metab. 1993, 4, 106-110 and references therein.
6. Ho, K. Y.; Evans, W. S.; Blizzard, R. M.; Veldhius, J. D.; Merriam, G. R.; Samojlik, E.; Furlanetto, R.; Rogol, A. D.; Kaiser, D. L.; Thorner, M. O. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations. J. Clin. Endocrinol. Metab. 1987, 64, 51-58.
7. Zadik, Z.; Chalew, S. A.; McCarter, R. J. Jr.; Meistas, M.; Kowarski, A. A. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J. Clin. Endocrinol. Metab. 1985, 60, 513-516.
8. Juul, A.; Bang, P.; Hertel, N. T.; Main, K.; Dalgaard, P.; Jorgensen, K.; Muller, J.; Hall, K.; Skakkebaek, N. E. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab. 1994, 78, 744-752.
9. Schwander, J. C.; Hauri, C.; Zapf, J.; Froesch, E. F. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 1983, 113, 297.
10. Thompson, L. V. Effects of age and training on skeletal-muscle physiology and performance. Phys. Ther. 1994, 74, 71-81.
11. (a) Rudman, D.; Feller, A. G.; Hoskote, N. S.; Gergans, G. A.; Lalitha, P. Y.; Goldberg, A. F.; Schlenker, R. A.; Cohn, L.; Rudman, I. W.; Mattson, D. E. Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 1990, 323, 1-8.
12. (b) Rudman, D.; Feller, A. G.; Cohn, L.; Shetty, K. R.; Rudman, I. W.; Draper, M. W. Effects of human growth hormone on body composition in elderly men. Horm. Res. 1991, 36, Suppl. 1, 73-81.
13. Welle, S.; Thornton, C.; Statt, M.; McHenry, B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J. Clin. Endocrinol. Metab. 1996, 81, 3239-3243.
14. Papadakis, M. A.; Grady, D.; Black, D.; Tierney, M. J.; Gooding, G. A.; Schambelan, M.; Grunfeld, C. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann. Intern. Med. 1996, 124, 708-716.
15. Yarasheski, K. E.; Zachwieja, J. J.; Campbell, J. A.; Bier, D. M. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am. J. Physiol. 1995, 268, E268-76.
16. (a) Chung, C. S.; Etherton, T. D.; Wiggins, J. P. Stimulation of swine growth by porcine growth hormone. J. Anim. Sci. 1985, 60 (Suppl. 1), 118-130.
17. (b) Moseley, W. M.; Paulissen, J. B.; Taylor, V. N.; Munyakazi, L.; Goodwin, M. C.; Alaniz, G. R.; Clafin, G. H. Recombinant bovine somatotrophin (rbST) improves growth performance in finishing beef steers. J. Anim. Sci. 1991, 69 (Suppl. 1), 313.
18. Takahashi, Y.; Kipnis, M.; Daughaday, W. H. Growth hormone secretion during sleep. J. Clin. Invest. 1968, 47, 2079-2090.
19. Bunt, J. C.; Boileau, R. A.; Bahr, J. M.; Nelson, R. A. Sex and training differences in human growth hormone levels during prolonged exercise. J. Appl. Physiol. 1986, 61, 1796-1801.
20. Zachmann, M. Interrelations between growth hormone and sex hormones: physiology and therapeutic consequences. Horm. Res. 1992, 38 (Suppl. 1), 1-8.
21. (a) Leung, D. W.; Spencer, S. A.; Cachianes, G.; Hammonds, R. G.; Collins, C.; Henzel, W. J.; Barnard, R.; Waters, M. J.; Wood, W. I. Growth hormone receptor and serum binding protein purification, cloning and expression. Nature 1987, 330, 537-543.
22. (b) Wallis, M. Growth hormone receptor cloned. Nature 1987, 330, 521-522.
23. Bermann, M.; Jaffe, C. A.; Tsai, W.; DeMott-Friberg, R.; Barkan, A. L.; Negative feedback regulation of pulsatile growth hormone secretion by insulin-like growth factor-1. J. Clin. Invest. 1994, 94, 138-145.
24. (a) Guillemin, R.; Brazeau, P.; Bohlen, P.; Esch, F.; Ling, N.; Wehrenberg, W. B. Growth hormone releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982, 218, 585-589.
25. (b) Rivier, J.; Speiss, J.; Thorner, M.; Vale, W. Characterization of a growth hormone-releasing factor from a pancreatic islet tumor. Nature 1982, 300, 276-278.
26. (a) Mayo, K. E. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol. Endocrinol. 1992, 6, 1734-1744.
27. (b) Gaylinn, B. D.; Harrison, J. K.; Zysk, J. R.; Lyons, C. E.; Lynch, K. R.; Thorner, M. O. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol. Endocrinol. 1993, 7, 77-84.
28. (a) Ling, N.; Baird, A.; Wehrenberg, W. B.; Ueno, N.; Munegumi, T.; Brazeau P. Synthesis and activity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochem. Biophys. Res. Commun. 1984, 123, 854-861.
29. (b) Campbell, R. M.; Lee, Y.; Rivier, J.; Heimer, E. P.; Felix, A. M.; Mowles, T. F. GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides 1991, 12, 569-574.
30. Labrie, F.; Gagne, B.; Lefrevre, G. Growth hormone-releasing factor stimulates adenylate cyclase activity in the anterior pituitary gland. Life Sci. 1983, 33, 2229.
31. (a) Low, L. C. K. Growth hormone-releasing hormone: clinical studies and therapeutic aspects. Neuroendocrinology 1991, 53 (Suppl. 1), 37.
32. (b) Thorner. M. O. On the discovery of growth hormone-releasing hormone. Acta Pediatr. 1993, 388 (Suppl.), 2.
33. Kubiak, T. M.; Friedman, A. R.; Moseley, W. M. Synthetic analogues of growth hormone releasing factor (GHRF) with improved pharmaceutical properties. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 31-52.
34. Vance, M. L.; Kaiser, D. L.; Evans, W. S.; Furlanetto, R.; Vale, W.; Rivier, J.; Thorner, M. O. Pulsatile growth hormone secretion in normal men during a 24-hour continuous infusion of growth hormone-releasing factor (1-40): evidence for intermittent somatostatin secretion. J. Clin. Invest. 1985, 75, 1584-1590.
35. 2 promotes growth over one year in short, slow growing children. Clin. Endocrinol. 1990, 32, 153-163.
36. 2 terminus. J. Clin. Invest. 1986, 78, 906-913.
37. Smith, D. P.; Heiman, L. M.; Wagner, J. F.; Jackson, R. L.; Bimm, R. A.; Hsiung, H. M. Production and biological activity of hybrid growth hormone-releasing hormone propeptides. Biotechnology 1992, 10, 315-319.
38. Campbell, R. M.; Bongers, J.; Felix, A. M. Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor (GRF) analogs. Biopolymers 1995, 37, 67-88.
39. Kubiak, T. M.; Friedman, A. R.; Martin, R. A.; Ichhpurani, A. K.; Alaniz, G. R.; Clafin, W. H.; et al. Position 2 and position2/ Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity. J. Med. Chem. 1993, 36, 888-897.
40. For a comprehensive review on the discovery of the GHRPs, see: Bowers, C. Y. Xenobiotic growth hormone secretagogues: Growth hormone releasing peptides. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 9-28.
41. Bowers, C. Y.; Chang, J.; Momany, F.; Folkers, K. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In Molecular Endocrinology; MacInytre, I., Ed.; Elsevier/North-Holland: Amsterdam, pp 287-292.
42. Bowers, C. Y.; Momany, F.; Reynolds, G. A.; Chang, D.; Hong, A.; Chang, K. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1981, 106, 663-667.
43. Momany, F. A.; Bowers, C. Y.; Reynolds, G. A.; Chang, D.; Hong, A.; Newlander, K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981, 108, 31-39.
44. Bowers, C. Y.; Momany, F. A.; Reynolds, G. A.; Hong, A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114, 1537-1545.
45. Momany, F. A.; Bowers, C. Y.; Reynolds, G. A.; Hong, A.; Newlander, K. Conformational energy studies and in vitro and in vivo activity data on growth-hormone releasing peptides. Endocrinology 1984, 114, 1531-1536.
46. 2 in rat primary pituitary cell monolayer culture. Endocrinology 1984, 116, 952-957. (b) Badger, T. M.; Millard, W. J.; McCormick, G. F.; Bowers, C. Y.; Martin, J. B. The effects of growth hormone (GH) releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984, 115, 1432-1438.
47. 2 in rat primary pituitary cell monolayer culture. Endocrinology 1984, 116, 952-957. (b) Badger, T. M.; Millard, W. J.; McCormick, G. F.; Bowers, C. Y.; Martin, J. B. The effects of growth hormone (GH) releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984, 115, 1432-1438.
48. Momany, F. A.; Bowers, C. Y. Computer-assisted modeling of xenobiotic growth hormone secretagogues. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 73-84.
49. 2 in rats, dogs and monkeys. Life Sci. 1990, 47, 29-36.
50. Doscher, M. E.; Baker, P. K.; Kraft, L. A.; Ricks, C. A. Effect of a synthetic growth hormone releasing peptide (BI 679) and growth hormone-releasing factor (GRF) on serum growth hormone levels in barrows. J. Anim. Sci. 1984, 59 (Suppl.), 109.
51. Kraft, L. A.; Baker, P. K.; Doscher, M. E.; Ricks, C. A. Effects of a synthetic growth hormone releasing peptide on serum growth hormone levels in steers. J. Anim. Sci. 1984, 59 (Suppl.), 218.
52. Hickey, G.; Jacks, T.; Judith, F.; Taylor, J.; Schoen, W. R.; Krupa, D.; Cunningham, P.; Clark, J.; Smith, R. G. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. Endocrinology 1994, 134, 695-701.
53. Bowers, C. Y.; Reynolds, G. A.; Durham, D.; Barrera, C. M.; Pezzoli, S. S.; Thorner, M. O. Growth hormone (GH) releasing peptide stimulates GH secretion in normal men and acts synergistically with GH releasing hormone. Endocrinology 1990, 70, 975-982.
54. Baker, P. K.; Conner, S. D.; Doscher, M. E.; Kraft, L. A.; Ricks, C. A. Use of a synthetic growth hormone releasing peptide to increase rate of body weight gain in rats. J. Anim. Sci. 1984, 59 (Suppl.), 220.
55. Croom, Jr J. W.; Leonard, E. S.; Baker, P. K.; Kraft, L. A.; Ricks, C. A. The effects of synthetic growth hormone releasing peptide BI 679 on serum growth hormone levels and milk production in lactating dairy cattle. J. Anim. Sci. 1984, 59 (Suppl.), 109.
56. Bowers, C. Y. In Molecular And Clinical Advances In Pituitary Disorders; Melmed, S., Ed.; Endocrine Research and Education: Los Angeles, CA, 1993; pp 153-157.
57. (a) Bowers, C. Y. GH releasing peptides - structure and kinetics. J. Pediatr. Endocrinol. 1993, 6, 21-31.
58. 2) in rat anterior-pituitary cells. Endocrinology 1993, 132, 1286-1291.
59. Deghenghi. R.; Cananzi, M. M.; Torsello, A.; Battisti, C.; Muller, E. E.; Locatelli, V. GH-Releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994, 54, 1321-1328.
60. Reynolds, G. A.; Bowers, C. Y. In vitro studies with GH releasing peptides. 69th Annual Meeting of The Endocrine Society, Indianapolis, IN, 1987; p 49 (Abstract).
61. Bowers, C. Y.; Sartor, A. O.; Reynolds, G. A.; Badger, T. M. On the actions of growth hormone releasing peptide, GHRP. Endocrinology 1991, 128, 2027-2035.
62. 2 on GHRF-stimulated GH release and intracellular adenosine 3′5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989, 124, 2791-2798.
63. Fairhall, K. M.; Mynett, A.; Smith, R. G.; Robinson, I. C. A. F. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the nonpeptide GH secretagogue, L-692,585. J. Endocrinol. 1995, 145, 417-426.
64. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
65. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
66. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
67. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
68. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
69. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
70. (a) For a recent review on the clinical actions of GHRPs, see: Ghigo, E.; Arvat, E.; Muccioli, G.; Camanni, F. Growth hormone releasing peptides. Eur. J. Endocrinol. 1997, 136, 445-460 and references therein. (b) Micic, D.; Kendereski, A.; Popovic, V.; Sumarac, M.; Macut, D.; Zoric, S.; Colic, M.; Zivkovic, D.; Dieguez, C.; Casanueva, F. Growth-hormone response to GHRH, GHRP-6 and GHRH+GHRP-6 in non-insulin-dependent diabetes-mellitus. Diabetologia 1996, 39, 697. (c) Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823. (d) Dieguez, C.; Cordido, E.; Leal, A.; Pombo, M.; Pumar, A.; Penalva, A.; Casanueva F. F. GHRP-6 induced GH secretion in three states of pathological hyposomatotropism: Cushing's syndrome, obesity and short stature children. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 228 (Abstract). (e) Giustina, A.; Bresciani, E.; Bugari, G.; Bussi, A. R.; Deghenghi, R.; Imbimbo, B.; Giustina, G. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocr. Res. 1995, 21, 569-582. (f) Kyrgialanis, A.; Kakavas, I.; Voudiclari, S.; Deghenghi, R.; Moschogianni, H.; Tolis, G. Pituitary somatotrope responsiveness to two growth hormone secretagogues: GRF (1-29) and the GHRP-hexarelin in hemodialysed patients with chronic renal failure (CRF). Nephrol. Dialysis Transplantation 1995, 10, 985 (Abstract). (g) Micic, D.; Kendereski, A.; Sumarac, M.; Zoric, S.; Colic, M.; Macut, D.; Dieguez. C.; Casanueva, F. Growth hormone secretion in patients with polycystic ovary disease after administration of GHRH, GHRP-6 and GHRH+GHRP-6. 10th International Congress of Endocrinology, San Francisco, CA, 1996; 3-52 (Abstract).
71. Pombo, M.; Barreiro, J.; Penalva, A.; Peino, R.; Dieguez, C.; Casanueva, F. F. Absence of growth-hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary-stalk transection. J. Clin. Endocrinol. Metab. 1995, 80, 3180-3184.
72. Popovic, V.; Damjanovic, S.; Micic, D.; Djurovic, M.; Doknic, M.; Dieguez, C.; Casanueva, F. Growth hormone secretion after GHRH and GHRP-6 in patients with hypothalamo-pituitary disconnection. J. Endocrinol. 1995, 144, P96 (Abstract).
73. Jaffe, C. A.; Ho, P. J.; Demottfriberg, R.; Bowers, C. Y.; Barkan, A. L. Effects of a prolonged growth-hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J. Clin. Endocrinol. Metab. 1993, 77, 1641-1647.
74. Huhn, W. C.; Hartman, M. L.; Pezzoli, S. S.; Thorner, M. O. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J. Clin. Endocrinol. Metab. 1993, 76, 1202-1208.
75. Klinger, B.; Silbergeld, A.; Deghenghi, R.; Frenkel, J.; Laron, Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur. J. Endocrinol. 1996, 134, 716-719.
76. Ghigo, E.; Arvat, E.; Gianotti, L.; Grottoli, S.; Rizzi, G.; Ceda, G. P.; Boghen, M. F.; Deghenghi, R.; Camanni, F. Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur. J. Endocrinol. 1996, 735, 407-412.
77. Mericq, V.; Cassorla, F.; Salazar, T.; Avila, A.; Iniguez, G.; Bowers, C. Y.; Merriam, G. R. Treatment with GHRP-2 accelerates the growth of GH deficient children. J. Invest. Med. 1996, 44, A 103.
78. Pihoker, C.; Kearns, G. L.; Bowers, C. Pharmacokinetics (PK) and pharmacodynamics (PD) of growth-hormone releasing peptide-2 (GHRP-2) - a phase-I study in children. J. Invest. Med. 1996, 44, A 60.
79. Laron, Z.; Frenkel, J.; Deghenghi, R.; Anin, S.; Klinger, B.; Silbergeld, A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin. Endocrinol. 1995, 43, 631-635.
80. Bowers, C. Y.; Alster, D. K.; Reynolds, G. A.; Frentz, J. M. GH release following oral administration of synthetic hexapeptide (GHRP) in normal men and GH deficient children. 72nd Annual Meeting of the Endocrine Society, Atlanta, GA, 1990; p297 (Abstract).
81. Bowers, C. Y.; Alster, D. K.; Frentz, J. M. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J. Clin. Endocrinol. Metab. 1992, 74, 292-298.
82. (a) Smith, R. G.; Cheng, K; Pong, S. S.; Hickey, H.; Jacks, T.; Butler, B.; Chan, W.-S.; Chaung, L. Y. P.; Judith, F.; Taylor, J. A.; Wyvratt, M. J.; Fisher, M. H. A Novel Non-Peptidyl Growth Hormone Secretagogue. Science 1993, 260, 1640-1643.
83. (b) Schoen, W. R.; Pisano, J. M.; Prendergast, K.; Wyvratt, M. J., Jr.; Fisher, M. H.; Cheng, K.; Chan, W. W. S.; Butler, B.; Smith, R. G.; Ball, R. G. A novel 3-substituted benzazepinone growth hormone secretagogue (L-692,429). J. Med. Chem. 1994, 37, 897-906.
84. (a) Horwell, D. C. Kappa opioid analgesics. Drugs Future 1988, 13, 1061-1071.
85. (b) Rees, D. C.; Hunter, J. C. Opioid receptors. In Comprehensive Medicinal Chemistry; Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, Vol. 3, pp 805-846.
86. Cheng, K; Chan, W. W.-S, Butler, B.; Wei, L.; Schoen, W. R.; Wyvratt, M. J.; Fisher, M. H.; Smith, R. G. Stimulation of growth hormone release from rat primary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology 1993, 132, 2729-2731.
87. Schoen, W. R.; Ok, D.; DeVita, R. J.; Pisano, J. M.; Hodges, P.; Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Smith, R. G.; Wyvratt, M. J., Jr.; Fisher, M. H. Structure-activity relationships in the amino acid sidechain of L-692,429. Bioorg. Med. Chem. Lett. 1994, 4, 1117-1122.
88. Ok, D.; Schoen, W. R.; Hodges, P.; DeVita, R. J.; Brown, J. E.; Chang, K.; Chan, W. W.-S.; Butler, B. S.; Smith, R. G.; Fisher, M. H.; Wyvratt, M. J., Jr. Structure activity relationships of non-peptidyl growth hormone secretagogue L-692,429. Bioorg. Med. Chem. Lett. 1994, 4, 2709-2714.
89. Hansen, T. K.; Thogersen, H.; Hansen, S. S. Naphtho-fused azepines as potent growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1997, 7, 2951-2954.
90. Jacks, T. M.; Hickey, G. J.; Judith, F.; Taylor, J.; Chen, H. Y.; Krupa, D. A.; Feeney, W. P.; Schoen, W. R.; Ok, D.; Fisher, M. H.; Wyvratt, M. J., Jr.; Smith, R. G. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J. Endocrinol. 1994, 143, 399-406.
91. (a) Gertz, B. J.; Barrett, J. S.; Eisenhandler, R.; Krupa, D. A.; Wittreich, J. A.; Seibold, J. R.; Schneider, S. H. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J. Clin. Endocrinol. Metab. 1993, 77, 1393-1397.
92. (b) Aloi, J. A.; Gertz, B. J.; Hartman, M. L.; Huhn, W. C.; Pezzoli, S. S.; Wittreich, J. M.; Krupa, D. A.; Thorner, M. A. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429 in healthy older subjects. J. Clin. Endocrinol. Metab. 1994, 79, 943-949.
93. Chapman, I. M.; Hartman, M. L.; Pezzoli, S. S.; Thorner, M. O. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone releasing peptide (GHRP)-mimetic, L-692,429, in older adults. J. Clin. Endocrinol. Metab. 1996, 81, 2874-2880.
94. Gertz, B. J.; Sciberras, D. G.; Yogendran, L.; Christie, K.; Bador, K.; Krupa, D.; Wittreich, J. M.; James, I. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion. J. Clin. Endocrin. Metab. 1994, 79, 745-749.
95. For pharmacokinetic properties of L-692,429, see: Leung, K. H.; Cohn, D. A.; Miller, R. R.; Doss, G. A.; Stearns, R. A.; Simpson, R. E.; Feeney, W. P.; Chui, S.-H. L. Pharmacokinetics and disposition of L-692,429, a novel nonpeptidyl growth hormone secretagogue in preclinical species. Drug Metab. Dispos. 1996, 24, 753-760.
96. DeVita, R. J.; Schoen, W. R.; Fisher, M. H.; Frontier, A. J.; Pisano, J. M.; Wyvratt, M. J., Jr.; Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Hickey, G. J.; Jacks, T. M.; Smith, R. G. Benzolactam growth hormone secretagogues: carboxamides as replacements for the 2′-tetrazole moiety of L-692,429. Bioorg. Med. Chem. Lett. 1994, 4, 2249-2254.
97. (a) Patchett, A. A.; Smith, R. G.; Wyvratt, M. J. Orally Active Growth Hormone Secretagogues. In Integration of Pharmaceutical Discovery: Case Histories; Borchardt, R. T., Sawyer, T., Freidinger, R., Smith, P., Eds.; 1997, in press.
98. (b) DeVita, R. J.; Schoen, W. R.; Ok, D.; Barash, L.; Brown, J. E.; Fisher, M. H.; Hodges, P.; Wyvratt, M. J., Jr.; Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Smith, R. G. Benzolactam growth hormone secretagogues: replacements for the 2′-tetrazole moiety of L-692,429. Bioorg. Med. Chem. Lett. 1994, 4, 1807-1812.
99. (c) DeVita, R. J.; Wyvratt, M. J., Jr. Benzolactam growth hormone secretagogues. Drugs Future 1996, 21, 273-281.
100. (d) Ankersen, M.; Peschke, B.; Hansen, B. S.; Hansen, T. K. Investigation of bioisosteres of the growth hormone secretagogue L-692,429. Bioorg. Med. Chem. Lett. 1997, 7, 1293-1298.
101. Nargund, R. P.; Barakat, K. J.; Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Smith, R. G.; Patchett, A. A. Synthesis and biological activities of camphor-based non-peptide growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1996, 6, 1265-1270.
102. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
103. Ariens, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. The pharmacon-receptor-effector concept, A basis for understanding the transmission of information in biological systems. In The Receptors, A comprehensive treatise, O'Brien, R. D., Ed.; Plenum Press: New York and London, 1979; pp 33-91.
104. Andrews, P. R.; Lloyd, E. J. Molecular conformation and biological activity of central nervous system active drugs. Med. Res. Rev. 1982, 2, 355-393.
105. Wiley: R. A.; Rich, D. H. Peptidomimetics derived from natural products. Med. Res. Rev. 1983, 13, 327-384.
106. Chambers, M. S.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Wong, E. H. F. Spiropiperidines as high-affinity, selective s ligands. J. Med. Chem. 1992, 35, 2033-2039.
107. Elliott, J. M.; Cascieri, M. A.; Davies, S.; Huscroft, I. T.; Kelleher, F. J.; Lewis, R. T.; MacLeod, A. M.; Merchant, K. J.; Sadowski, S.; Stevenson, G. I. Serine derived NK1 antagonists. 211th American Chemical Society National Meeting, New Orleans, LA, 1996; MEDI 075 (Abstract).
108. Lowe, J. A.; McLean, S. Tachykinin antagonists. Curr. Pharm. Des. 1995, 1, 269-278.
109. Smith, P. W.; Cooper, A. W. J.; Bell, R.; Beresford, I. J. M.; Gore, P. M.; McElroy, A. B.; Pritchard, J. M.; Saez, V.; Taylor, N. R.; Sheldrick, R. L. G.; Ward, P. New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists. J. Med. Chem. 1995, 38, 3772-3779.
110. Shah, S. K.; Hale, J. J.; Qi, H.; Miller, D. J.; Dorn, C. P.; Mills, S. G.; Sadowski, S. J.; Cascieri, M. A.; Metzger, J. M.; Eiermann, G. J.; Forrest, M. J.; MacIntyre, D. E.; MacCoss, M. Discovery of substituted spiroindolinepiperidines as orally active dual antagonists of NK1 and NK2 receptors. 212th American Chemical Society National Meeting, Orlando, FL 1996; MEDI 136 (Abstract).
111. deLaszlo, S. E.; Allen, E. E.; Li, B.; Ondeyka, D.; Rivero, R.; Malkowitz, L.; Molineaux, C.; Siciliano, S. J.; Springer, M. S.; Greenlee, W. J.; Mantlo, N. A nonpeptide agonist ligand of the human C5a receptor: synthesis, binding affinity optimization and functional characterization. Bioorg. Med. Chem. Lett. 1997, 7, 213-218.
112. Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M.-H.; Barkat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Hickey, G.; Jacks, T.; Schleim, K.; Pong, S.-S.; Chaung, L. Y.-P.; Chen, H. Y.; Frazier, E.; Leung, K. H.; Chiu, S.-H. L.; Smith, R. G. Design and biological activities of L-163,191 (MK-0677): A potent orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7001-7005.
113. Chen, M.-H.; Steiner, M. G.; Patchett, A. A.; Cheng, K.; Wei, L.; Chan, W. W.-S.; Butler, B.; Jacks, T. M.; Smith, R. G. Analogs of the orally active growth hormone secretagogue L-162,752. Bioorg. Med. Chem. Lett. 1996, 6, 2163-2168.
114. Smith, R. G.; Pong, S.-S.; Hickey, G.; Jacks, T.; Cheng, K.; Leonard, R.; Cohen, C. J.; Arena, J. P.; Chang, C. H.; Drisko, J.; Wyvratt, M.; Fisher, M.; Nargund, R.; Patchett, A. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. In Recent Progress In Hormone Research; Conn, P. M., Ed.; The Endocrine Society: Bethesda, 1996; Vol. 51, pp 261-286.
115. Pong, S.-S.; Chaung, L.-Y. P.; Dean, D. C.; Nargund, R. P.; Patchett, A.
116. Jacks, T.; Smith, R.; Judith, F.; Schleim, K; Frazier, E.; Chen, H.; Krupa, D.; Hora, D., Jr.; Nargund, R.; Patchett, A.; Hickey, G. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996, 137, 5284-5289.
117. Hickey, G.; Jacks, T.; Schleim, K.; Frazier, E.; Chen, H.; Krupa, D.; Feeney, W.; Nargund, R.; Patchett, A.; Smith, R. G. Repeat administration of the growth hormone secretagogue MK-0677 increases and maintains elevated IGF-1 levels in beagles. J. Endocrinol. 1997,152, 183-192.
118. Jacks, T.; Lieber, R.; Schleim, K.-D.; Mohler, R.; Haven, M.; Feeney, W.; Hora, D.; Hickey, G. L-163,255, a GH secretagogue, increased muscle torque in the remobilization phase of a canine hind limb model. 10th International Congress of Endocrinology, San Francisco, CA, 1996; P1-602 (Abstract).
119. Chang, C. H.; Rickes, E. L.; McGuire, L.; Frazier, E.; Chen, H.; Barakat, K.; Nargund, R.; Patchett, A.; Smith, R. G.; Hickey, G. J. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine. Endocrinology 1996, 737, 4851-4856.
120. Snyder, D. K.; Clemmons, D. R.; Underwood, L. E. Treatment of obese, diet restricted subjects with growth hormone for 11 weeks: Effects of anabolism, lipolysis and body composition. J. Clin. Endocrinol. Metab. 1988, 67, 54-61.
121. Manson, J. McK.; Wilmore, D. W. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery 1986, 700, 188-97.
122. Isley, W. L.; Underwood, L. E.; Clemmons, D. R. Dietary components that regulate serum somatomedin-C in humans. J. Clin. Invest. 1983, 71, 175-182.
123. Ho, K. Y.; Veldhuis, J. B.; Johnson, M. L.; Furlanetto, R.; Evans, W. S.; Alberti, K. G. M.; Thorner, M. O. Fasting enhances growth hormone secretion and amplifies the complex synthesis of growth hormone secretion in man. J. Clin. Invest. 1988, 81, 968-975.
124. Clemmons, D. R.; Plunkett, L. J.; Polvino, W. M. Administration of the GH secretagogue L-163,191 stimulates an anabolic response in calorically restricted normal volunteers. Endocrinol. Metab. 1997, 4 (Suppl. A), 35 (Abstract).
125. Chapman, I. M.; Bach, M. A.; Van Cauter, E.; Farmer, M.; Krupa, D.; Taylor, A. M.; Schilling, L. M.; Cole, K. Y.; Skiles, E. H.; Pezzoli, S. S.; Hartman, M. L.; Veldhuis, J. D.; Gormley, G. J.; Thorner, M. O. Stimulation of the growth hormone (GH)/IGF-I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 1996, 87, 4249-4257.
126. Veldhuis, J.; Iranmesh, A.; Waters, M.; et al. Dual defects in pulsatile GH secretion and clearance subserve the hyposomatotrophism in man. J. Clin. Endocrin. Metab. 1991, 72, 51-59.
127. Cordido, F.; Penalva, A.; Dieguez, C.; Casanueva, F. F. Massive growth-hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6 - evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 1993, 76, 819-823.
128. Svensson, J.; Lonn, L.; Jansson J.-O.; Murphy, G.; Wyss, D.; Krupa, D.; Cerchio, K.; Gertz, B.; Bosaeous, I.; Sjostrom, L.; Bengtsson, B.-A. Two months treatment of obese subjects with GH secretagogue MK-677 increases fat-free mass and insulin-like growth factor1 (IGF-I). Endocrinol. Metab. 1997, 4 (Suppl. A), 35 (Abstract).
129. Dickson, S.; Luckman, S. Induction of c-fos mRNA in NPY and GRF neurones in the rat arcuate nucleus following systemic injection of the GH secretagogue, GHRP-6. Endocrinology 1997, 138, 771-777.
130. Clark, J.; Kalra, P.; Kairs S. Neuropeptide Y and human pancreatic polypeptide stimulate feeding in rats. Endocrinology 1984, 115, 427-429.
131. Williams, P. D.; Anderson, P. S.; Ball, R. G.; Bock, M. G.; Carroll, L. A.; Chiu, S.-H. L.; Clineschmidt, B. V.; Culberson, J. C.; Erb. J. M.; Evans, B. E.; Fitzpatrick, S. L.; Freidinger, R. M.; Kaufman, M. J.; Lundell, G. F.; Murphy, J. S.; Pawluczyk, J. M.; Perlow, D. S.; Pettibone, D. J.; Pitzenberger, S. M.; Thompson, K. L.; Veber, D. F. 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butryramido)bicyclo[2.2.1]- heptan-1(S)-yl)methyl)-sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. J. Med. Chem. 1994, 37, 565-571.
132. Barakat, K. J.; Prendergast, K. J.; Cheng, K.; Jacks, T. M.; Schleim, K.; Chan, W. W.-S.; Butler, B.; Frazier, E.; Hickey, G. J.; Smith, R. G.; Patchett, A. A.; Nargund, R. P. Design and biological activities of aryl piperazine-based growth hormone secretagogues. Bioorg. Med. Chem. Lett., in press.
133. Tata, J. R.; Lu, Z.; Cheng, K.; Wei, L.; Chan, W. W.-S.; Butler, B.; Schleim, K. D.; Jacks, T. M.; Leung, K.; Chiu, S.-H. L.; Hickey, G.; Smith, R. G.; Patchett, A. A. The design and synthesis of orally active short duration spiroindane growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1997, 7, 2319-2324..
134. Lefker, B. A.; Carpino, P. A.; Pan, L. C.; Chidsey-Frink, K. L.; DiSilva-Jardine, P.; DiCapua, F. M.; Griffith, D. A.; Hada, W. A.; Inthavongsay, J. K.; Lewis, S. K.; Mangano, F. M.; Murray, M. C.; Ng, O.; Owens, J. G.; Pirie, C. M.; Rose, C. R.; Ryan, N. I.; Schafer, J. R.; Tucker, J. L.; Wright, A. S.; Zawistoski, M. P.; Thompson, D. D. The design, synthesis and biological activities of a series of tetrahydroquinoline/isoindole-based growth hormone secretagogues. In Growth Hormone Secretagogues in Clinical Practice; Bercu, B. B., Walker, R. F., Eds.; Marcel Dekker: New York, 1998; pp 107-120.
135. Bochis, R. J.; Wyvratt, M. J.; Schoen, W. R. U.S. Patent No. 5,-283,241.
136. Yang, L.; Morriello, G.; Prendergast, K.; Cheng, K.; Jacks, T.; Chan, W. W.-S.; Schleim, K. D.; Smith, R. G.; Patchett, A. A. Potent 3-spiropiperidine growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1998, 8, 107-112.
137. Yang, L.; Morriello, G. J.; Patchett, A. A.; Leung, K.; Jacks, T.; Cheng, K.; Schleim, K.; Chan, W.; Chiu, S.-H. L.; Smith, R. G. L-163,540, a potent and orally bioavailable short duration growth hormone secretagogue. 215th American Chemical Society National Meeting, Dallas, TX, 1998; MEDI 020 (Abstract).
138. Carpino, P. A.; Jardine, D. P. A.; Lefker, B. A.; Ragan, J. A. PCT Patent Publication WO97/24369.
139. Dodge, J. A.; Hipskind, P. A. PCT Patent Publication WO97/ 07117.
140. (a) Dodge, J. A.; Hipskind, P. A. PCT Patent Publication WO97/ 06803.
141. (b) Hipskind, P. A.; Howbert, J. J.; Bruns, R. F.; Cho, S. S. Y.; Crowell, T. A.; Foreman, M. M.; Gehlert, D. R.; Iyengar, S.; Johnson, K. W.; Krushinski, J. H.; Li, D. L.; Lobb, K. L.; Mason, N. R.; Muehl, B. S.; Nixon, J. A.; Phebus, L. A.; Regoli, D.; Simmons, R. M.; Threlkeld, P. G.; Waters, D. C.; Gitter, B. D. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J. Med. Chem. 1996, 39, 736-748.
142. McDowell, R. S.; Elias, K. A.; Stanley, M. S.; Burdick, D. J.; Burner, J. P.; Chan, K. S.; Fairbrother, W. J.; Hammond, R. G.; Ingle, G. S.; Jacobsen, N. E.; Mortensen, D. L.; Rawson, T. E.; Won, W. B.; Clark, R. G.; Somers, T. C. Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11165-11169.
143. Elias, K. A.; Ingle, G. S.; Burnier, J. P.; Hammonds, R. G.; McDowell, R. S.; Rawson, T. E.; Somers, T. C.; Stanley, M. S.; Cronin, M. J. In vitro characterization of four novel classes of growth hormone-releasing peptides. Endocrinology 1995, 136, 5694-5699.
144. Somers, T. K.; Elias, K. A.; Clark, R. G.; McDowell, R. S.; Stanley, M. S.; Burnier, J. P.; Rawson, T. E. PCT Patent Publication WO 96/15148.
145. Deghenghi, R. Growth hormone releasing peptides. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 85-102.
146. Deghenghi, R.; Boutignon, F.; Luoni, M.; Grilli, R.; Guidi, M.; Locatelli, V. Small peptides as potent releasers of growth hormone. J. Pediat. Endocrinol. Metab. 1995, 8, 311-313.
147. Deghenghi, R.; Boutignon, F.; Luoni, M.; Grilli, R.; Guidi, M.; Locatelli, V. Characterization of the activity of new growth hormone secretagogues in the infant rat. 10th International Congress of Endocrinology, San Francisco, CA, 1996; P1-581 (Abstract).
148. Deghenghi, R.; Boutignon, F.; Luoni, M.; Rigamonti, A.; Cella, S. G.; Broglio, F.; Arvat, E.; Ghigo, E.; Locatelli, V. Small impervious peptides as GH secretagogues. 2nd International Symposium on Growth Hormone Secretagogues, Tampa, FL, February 13-16, 1997; P9 (Abstract).
149. Deghenghi, R. PCT Patent Publication W097/2260.
150. 1(127) Hansen, B. S.; Raun, K. GH secretagogues - potency and efficacy are "model" dependent. 10th International Congress of Endocrinology, San Francisco, CA, 1996; P1 583 (Abstract).
151. Johansen, P. B.; Hansen, K. T.; Andersen, J. V.; Jensen, M.; Jensen, M. Pharmacokinetics of growth hormone releasing peptides in the rat. 10th International Congress of Endocrinology San Francisco, CA, 1996; P1 585 (Abstract).
152. Johansen, N. L.; Hansen, B. S.; Kligaard, H.; Ankersen, M. Structure activity relationships of GHRP analogs. In 10th International Congress of Endocrinology, San Francisco, CA, 1996; P1 586 (Abstract).
153. Peschke, B.; Madsen, K.; Hansen, B. S.; Johansen, N. L. Aminomethylthiophene-2-carboxylic acids as dipeptide mimetic in new growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1997, 7, 1969-1972.
154. Johansen, N. L.; Lau, J.; Madsen, K.; Thoegersen, H., Lundt, B. F.; Peschke, B.; Hansen, T. K.; Hansen, B. S. PCT Patent Publication WO97/00894.
155. Hansen, T. K.; Peschke, B.; Lau, J.; Lundt, B. F.; Ankersen, M.; Watson, B.; Madsen, K. PCT Patent Publication WO97/23508.
156. Dean, D. C.; Nargund, R. P.; Pong, S.-S.; Chaung, L.-Y. P.; Griffin, P.; Melillo, D. G.; Ellsworth, R. L.; Van Der Ploeg, L. H. T.; Patchett, A. A.; Smith, R. G. Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. 1996, 39, 1767-1770.
157. Schwartz, T. W.; Rosenkilde, M. M. Is there a 'lock' for all agonist 'keys' in TTM receptors? Trends Pharmacol. Sci. 1996, 17, 213-216.
158. Blake, A. D.; Bot, G.; Reisine, T. Structure-function analysis of the cloned opiate receptors: peptide and small molecule interactions. Chem. Biol. 1996, 3, 967-972.
159. Howard, A. D.; Feighner, S. D.; Cully, D. F.; Arena, J. P.; Liberator, P. A.; Rosenblum, C. I.; Hamelin, M.; Hreniuk, D. L.; Palyha, O. C.; Anderson, J.; Paress, P. S.; Diaz, C.; Chou, M.; Liu, K. K.; McKee, K. K.; Pong, S.-S.; Chaung, L.-Y. P.; Elbrecht, A.; Dashkevicz, M.; Heavens, R.; Rigby, M.; Sirinathsinghji, D. J. S.; Dean, D. C.; Melillo, D. G.; Patchett, A. A.; Nargund, R. P.; Griffin, P. R.; DeMartino, J. A.; Gupta, S. K.; Schaeffer, J. M.; Smith, R. G.; Van der Ploeg, L. H. T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273, 974-977.
160. Strader, C. D.; Sigal, I. S.; Register, R. B.; Candelore, M. R.; Rands, E.; Dixon, R. A. Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 4384-4388.
161. Strnad, J.; Hadcock, J. R. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem. Biophys. Res. Commun. 1995, 216, 913-921.
162. Feighner, S. D.; Howard, A. D.; Prendergast, K.; Palyha, O. C.; Hreniuk, D. L.; Nargund, R.; Underwood, D.; Tata, J. R.; Dean, D. C.; Tan, C.; McKee, K. K.; Woods, J. W.; Patchett, A. A.; Smith, R. G.; Van der Ploeg, L. H. T. Structural requirements for the activation of the human growth hormone secretagogue receptor. Mol. Endocrinol. 1998, 12, 137-145.
163. Wyvratt, M. J. Nonpeptidyl growth hormone secretagouges. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 103-117.
164. DeVita, R. J.; Frontier, A. J.; Schoen, W. R.; Wyvratt, M. J.; Fisher M. H.; Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Smith, R. G. Design and synthesis of potent macrocyclic benzolactam growth hormone secretagogues. Helv. Chim. Acta 1997, 80, 1244-1259.
165. (a) Yang, L.; Nargund, R.; Morriello, G.; Barakat, K.; Pan, Y.; Prendergast, K.; Cheng, K.; Chan, W. W.-S.; Smith, R. G.; Patchett, A. A. Tripeptide growth hormone secretagogues. 210th American Chemical Society National Meeting, Chicago, IL, 1995; MEDI 011 (Abstract).
166. (b) Yang, L.; Morriello, G.; Pan, Y.; Nargund, R.; Barakat, K.; Prendergast, K.; Cheng, K.; Chan, W. W.-S.; Smith, R. G.; Patchett, A. A. Tripeptide growth hormone secretagogues. Bioorg. Med. Chem. Lett. 1998, 8, 759-764.
167. Henke B. R.; Aquino, C. J.; Birkemo, L. S.; Croom, D. K.; Dougherty, R. W., Jr.; Ervin, G. N.; Grizzle, M. K.; Hirst, G. C.; James, M. K.; Johnson, M. F.; Queen, K. L.; Sherrill, R. G.; Sugg, E. E.; Suh, E. M.; Szewczyk, J. W.; Unwalla, R. J.; Yingling, J.; Willson, T. M. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J. Med. Chem. 1997, 40, 2706-2725 and references therein.
168. 2 receptor. Mol. Pharmacol. 1997, 52, 16-20.
169. 1 receptor. J. Biol. Chem. 1995, 270, 1493-1496.
170. Nargund, R.; Patchett, A. A. PCT Patent Publication WO 96/ 13265.
171. Morriello, G.; Patchett, A. A.; Yang, L.; Chen, M.-H.; Nargund, R. PCT Patent Publication WO 95/13069.
172. Skuker, S. B.; Hajduk, P. J.; Meadows, R. P.;, Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
173. Hirschmann, R.; Nicolau, K. C.; Pietranico, S.; Salvino J.; Leahy, E. M.; Sprengler, P. A.; Furst, G.; Smith, A. B. III; Strader, C. D.; Casieri, M. A.; Candelore, M. R.; Donaldson, C.; Vale, W.; Maechler, L. Nonpeptidal peptidomimetics with a b-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent selective substance P antagonist. J. Am. Chem. Soc. 1992, 114, 9217-9218.
174. (a) Smith, R. G.; Cheng, K.; Pong, S.-S.; Leonard, R. J.; Cohen, C. J.; Arena, J. P.; Hickey, G. J.; Chang, C. H.; Jacks, T. M.; Drisko, J. E.; Robinson, I. C. A. F.; Dickson, S. L.; Leng, G. Mechanism of Action of GHRP-6 and Nonpeptidyl Growth Hormone Secretagogues. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 147-163. 205.
175. (b) Smith, R. G.; Van der Ploeg, L. H. T.; Howard, A. D.; Feighner, S. D.; Cheng, K.; Hickey, G. J.; Wyvratt, M. J., Jr.; Fisher, M. H.; Nargund, R. P.; Patchett, A. A. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 1997, 18, 621-645.
176. 2) stimulates growth hormone secretion by depolarization in rat pituitary cell cultures. 73rd Annual Meeting of The Endocrine Society, Washington, DC, 1991; p80 (Abstract).
177. Pong, S.-S.; Chaung, L.-Y. P.; Smith, R. G.; Ertel, E. A.; Smith, M. M.; Cohen C. J. Role of calcium channels in growth hormone secretion induced by GHRP-s (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and other secretagogues in rat somatotrophs. 74th Annual Meeting of The Endocrine Society, San Antonio, TX, 1992; p14b (Abstract).
178. Leonard, R. J.; Chaung, L.-Y. P.; Pong, S.-S. Ionic conductances of identified rat somatotroph cells studies by perforated patch recording are modulated by growth hormone secretagogues. Biophys. J. 1991, 59, 254a (Abstract).
179. 2-induced growth hormone release from rat primary pituitary cells. Endocrinology 1991, 129, 3337-3342.
180. Mau S. E.; Witt, M. R.; Bjerrum, O. J.; Saermark, T.; Vilhardt, H. Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-trisphosphate/diacylglycerol pathway in rat anterior pituitary cells. J. Recept. Signal Transduct. Res. 1995, 15, 311-323.
181. Herrington, J.; Hille, B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotrophs by two mechanisms. Endocrinology 1994, 135, 1100-1108.
182. Bresson-Bepoldin, L.; Dufy-Barbe, L. GHRP-6 induces a biphasic calcium response in rat pituitary somatotrophs. Cell Calcium 1994, 15, 247-258.
183. 2 stimulates growth hormone release through distinct receptor sites. J. Endocrinol. 1991, 129, 11-19.
184. Cheng, K.; Chan, W. W.-S.; Butler, B. S.; Wei, L.; Smith, R. G. A novel nonpeptidyl growth hormone secretagogue. Horm. Res. 1993, 40, 109-115.
185. Nargund, R. P.; Feighner, S.; Hreniuk, D.; Dashkevicz, M.; Cheng, K.; Chan, W.-W. S.; Van Der Ploeg, L. H. T.; Smith, R. G.; Patchett, A. A. Novel probes derived from MK-0677 tor characterization of the growth-hormone secretagogue receptor. 212th American Chemical Society National Meeting, Orlando, FL 1996; MEDI 009 (Abstract).
186. Hreniuk, D. L.; Howard, A. D.; Rosenblum, C. I.; Palyha O. C.; Diaz, C.; Cully, D. F.; Paress, P. S.; McKee, K. K.; Dashkevicz, M.; Arena, J. P.; Liu, K. K.; Schaeffer, J. M.; Nargund, R. P.; Smith, R. G.; Van der Ploeg, L. H. T.; Feighner, S. D. Cytochemical identification and cloning of a G-protein coupled growth hormone secretagogue receptor. Soc. Neurosci. 1996, 22, 1300 (Abstract).
187. Chaung, L.-Y. P.; Pong, S.-S.; Dean, D.; Schaeffer, J. M.; Smith, R. G. Characterization of a G-protein-linked receptor for peptidyl and nonpeptidyl growth hormone secretagogue in rat and porcine hypothalamic and pituitary membranes. 10th International Congress of Endocrinology, San Francisco, CA, 1996; P1-613 (Abstract).
188. Adams, E. F.; Petersen, B.; Lei, T.; Buchfelder, M.; Fahlbusch, R. The growth hormone secretagogue, L-692, 429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochem. Biophys. Res. Commun. 1995, 208, 555-561.
189. Adams, M. E.; Olivera, B. M. Neurotoxins: overview of an emerging research technology. Trends Neurosci. 1994, 17, 151-155.
190. Olivera, B. M.; Miljanich, G. P.; Ramachandran, J.; Adams, M. E. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and the omega-agatoxins. Annu. Rev. Biochemistry 1994, 33, 823-867.
191. Ertel, E. A.; Warren, V. A.; Adams, M. E.; Griffin, P.; Cohen, C. J.; Smith, M. M. Type III omega-agatoxins: a family of probes for similar binding sites on L- and N-type calcium channels. Biochemistry 1994, 33, 5098-5108.
192. McGurk, J. F.; Pong, S.-S.; Chaung, L.-Y. P.; Gall, M.; Butler, B. S.; Arena, J. P. Growth hormone secretagogues modulate potassium currents in rat somatotrophs. Soc. Neurosci. 1993, 19, 1559 (Abstract).
193. Pong, S.-S.; Chaung, L.-Y. P.; Leonard, R. J. The involvement of ions in the activity of a novel growth hormone secretagogue L-692,429 in rat pituitary cell culture. 75th Annual Meeting of The Endocrine Society, Las Vegas, NV, 1993; p 172 (Abstract).
194. Koch, B. D.; Blalock, J. B.; Schonbrunn, A. Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J. Biol. Chem, 1988, 263, 216-225.
195. Mayo, K. E.; Godfrey, P. A.; DeAlmeida, V.; Miller, T. Structure, function, and regulation of the pituitary receptor for growth hormone releasing hormone. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 53-71.
196. Tang, W.-J.; Gilman, A. G. Type specific regulation of adenylyl cyclase by G protein bg subunits. Science 1991, 254, 1500-1503.
197. Maggio, R.; Vogel, Z.; Wess, J. Reconstitution of functional muscarinic receptors by co-expression of amino-carboxyl-terminal receptor fragments. FEBS 1993, 319, 195-200.
198. Aqua, M. S.; Rizzu, P.; Lindsay, E. A.; Shaffer, L. G.; Zackai, E. H.; Overhauser, J.; Baldini, A. Duplication of 3q syndrome: molecular delineation of the critical region. Am. J. Med. Genet. 1995, 55, 33-37.
199. (a) Brachmann, W.E Fall von symmetrischer Monodaktylie durch ulnadefekt mit symmetrischer Flughautbildung in den Ellenbeugen, sowie, anderen Abnormitaten (Zwerghaftigheit, Halsrippen, Behaarung). Jahrb Kinderkeilk. 1916, 84, 224-235.
200. (b) de Lange, C. Sur un type nouveau de degeneration (Typus Amstelodamensis). Arch. Med, Enf. 1933, 36, 713-718.
201. Dickson, S. L. Evidence for a central site and mechanism of action of growth hormone releasing peptide (GHRP-6). In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 237-251.
202. Fairhall, K. M.; Mynett, A.; Thomas, G. B.; Robinson, I. C. A. F. Central and peripheral effects of peptide and nonpeptide GH secretagogues in vivo. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 219-236.
203. Wehrenberg, W. B.; Brazeau, P.; Luhen, R.; Bohlen, P.; Guillemin, R. Inhibition of the pulsatile secretion by monoclonal antibodies to the hypothalamic growth hormone releasing factor (GRF). Endocrinology 1982, 111, 2147-2148.
204. Hickey, G. J.; Drisko, J. E.; Faidley, T. D.; Chang, C. H.; Anderson, L. L.; Nicolich, S.; McGuire, L.; Rickes, E. L.; Krupa, D. A.; Feeney. W. P.; Friscino, B. F.; Cunningham, P.; Frazier, E.; Chen, H. Y.; Laroque, P.; Smith, R. G. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J. Endocrinol. 1996, 148, 371-380.
205. Guillaume, V.; Magnan, E.; Cataldi, M.; Dutour, A.; Sauze, N.; Renard, M.; Razafindraibe, H.; Conte-Devolx, B.; Deghenghi, R.; Lenaerts, V.; Oliver, C. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994, 135, 1073-1076.
206. Fletcher, T. P.; Thomas, G. B.; Clarke, I. J. Growth hormone-releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6. Domes. Anim. Endocrinol. 1996, 13, 251-258.
207. Dickson, S. L.; Leng, G.; Dyball, R. E. J.; Smith, R. G. Central actions of peptide and nonpeptide growth hormone secretagogues in the rat. Neuroendocrinology 1995, 61, 36-43.
208. Sirinathsinghji, D. J. S.; Chen, H. Y.; Hopkins, R.; Trumbauer, M.; Heavens, R.; Rigby, M.; Smith, R. G.; Van der Ploeg, L. H. T. Induction of c-fos mRNA in the arcuate nucleus of normal and mutant growth hormone-deficient mice by a synthetic non-peptidyl hormone secretagogue. Neuro. Report 1996, 6, 1989-1992.
209. Bailey, A.; Smith, R. G.; Leng, G. Activation of hypothalamic arcuate neurons in the urethane-anesthetized rat following systemic injection of growth-hormone secretagogues. J. Physiol. London 1996, 495, 115-116.
210. Locke, W.; Kirgis, H. D.; Bowers, C. Y.; Abdoh, A. A. Intracerebroventricular growth hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci. 1995, 56, 1347-1352.
211. Wahlestedt, C.; Skagerberg, G.; Ekman, R.; Heilig, M.; Sundler, F.; Hakanson, R. Neuropeptide (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat. Brain Res. 1987, 417, 33-38.
212. Alvers, H. E.; Ottenweller, J. E.; Liou, S. Y.; Lumpkin, M. D.; Anderson, E. R. Neuropeptide Y in the hypothalamus: effect of corticosteroid and single-unit activity. Am. J. Physiol. 1990, 258, R376-R382.
213. Guan, X.-M.; Yu, H.; Palyha, O. C.; McKee, K. K.; Feighner, S. D.; Sirinathsinghji, D. J. S.; Smith, R. G.; Van der Ploeg, L. H. T.; Howard, A. D. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol. Brain Res. 1997, 48, 23-29.
214. Eichenbaum, H.; Otto, T.; Cohen, N. J. The hippocampus - what does it do? Behav. Neural. Biol. 1992, 57, 2-36.
215. Pohorecki, R.; Domino, E. F. Synaptic pharmacology of the hippocampus. Rev. Clin. Basic Pharm. 1987, 6, 189-211.
216. Fallon, J. G.; Loughlin, S. E. Substantia nigra. In The Rat Nervous System; Paxinos, G., Ed.; Academic Press: San Diego, 1995; pp 215-237.
217. Halliday, G.; Harding, A.; Paxinos, G. Serotonin and tachykinin systems. In The Rat Nervous System; Paxinos, G., Ed.; Academic Press: San Diego, 1995; pp 929-974.
218. Jansson, J. O.; Eden, S.; Isaksson, O. Sexual dimorphism in the control of growth hormone secretion. Endocr. Rev. 1985, 6, 128-150.
219. Davis, S. L.; Ohlson, D. L.; Klindt, J.; Anfinson, M. S. Episodic growth hormone secretory patterns in sheep: relationship to gonadal steroid hormones. Am. J. Physiol. 1977, 233, E519.
220. Miller, J. D.; Tannenbaum, G. S.; Colle, E.; Guyda, H. J. Daytime pulsatile growth hormone secretion during childhood and adolescence. J. Clin. Endocrinol. Metab. 1982, 55, 989-994.
221. Chihara, K.; Minamitani, N.; Kaji, H.; Kodama, H.; Kita, T.; Fujita, T. Human pancreatic growth hormone-releasing factor stimulates release of growth hormone in conscious unrestrained male rabbits. Endocrinology 1983, 113, 2081.
222. Gevers, E. F.; Wit, J. M.; Robinson, I. C. A. F. Growth, growth hormone (GH)-binding protein, and GH receptors are differentially regulated by peak and trough components of the GH secretory pattern in the rat. Endocrinology 1996, 137, 1013-1018.
223. Lumpkin, M. D.; McDonald, J. K. Blockade of growth hormone-releasing factor (GRF) activity in the pituitary and hypothalamus of the conscious rat with a peptidic GRF antagonist. Endocrinology 1989, 124, 1522-1531.
224. Tannenbaum, G. S.; Ling, N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in the generation of the ultradian rhythm of GH secretion. Endocrinology 1984, 115, 1952-1957.
225. Plotsky, P. M.; Vale, W. Patterns of growth hormone-releasing factor and somatostatin into the hypophysial postal circulation of the rat. Science 1985, 230, 461-463.
226. Chihara, K.; Minamitani, N.; Kaji, H.; Arimura, A.; Fujita, T. Intraventricularly injected growth hormone stimulates somatostatin release into rat hypophysial portal blood. Endocrinology 1981, 109, 2279-2281.
227. Carlsson, L. M. S.; Jansson, J. O. Endogenous growth hormone (GH) secretion in male rats is synchronized to pulsatile GH infusions given at 3-hour intervals. Endocrinology 1990, 126, 6-10.
228. Abe, H.; Molitch, M. E.; van Wyk, J. J.; Underwood, L. E. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology 1983, 113, 1319-1324.
229. Clark, R. G.; Carlsson, L. M. S.; Robinson, I. C. A. F. Growth hormone (GH) secretion in the conscious rat: negative feedbacK of GH on its own release. Endocrinology 1988, 119, 201-209.
230. Fletcher, T. P.; Thomas, G. B.; Willoughby, J. O.; Clarke, I. J. Constitutive growth hormone secretion in sheep after hypothalamopituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6. Neuroendocrinology 1994, 60, 76-86.
231. Dickson, S. L.; Doutrelant-Viltart, O.; McKenzie, D. N.; Dyball, R. E. J. Somatostatin inhibits arcuate neurons excited by GH-releasing peptide (GHRP-6) in rat hypothalamic slices. J. Physiol. London 1996, 495, 109-110.
232. Wu, D.; Chen, C.; Zhang, J.; Bowers, C. Y.; Clarke, I. J. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′,5′-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. J. Endocrinol. 1996, 148, 197-205.
233. Locatelli, V.; Torsello, A.; Grilli, R.; Guidi, M.; Luoni, M.; Deghenghi, R.; Muller, E. E. Growth hormone-releasing peptides stimulate feeding idependently of their GH releasing activity. 1996 Growth Hormone Research Society Conference, London, U, November 13-16, 1996; O-063 (Abstract).